<prompt> New drug for tardive dyskinesia:SafinamideTetrabenazineValbenazineDeutetrabenazine  <response>: C i.e. ValbenazineRef: accessdata. fda. govdrugsatfda_docslabel2017209241lbl. pdfExplanation:Valbenazine:Vesicular monoamine transporter 2 VMAT2 inhibitor.Specifically indicated for the treatment of adults with tardive dyskinesia.Supplied as a capsule for oral administration.Tetrabenazine:Centrally-acting dopamine depletor.Selective and reversible.Used in chorea associated with Huntingtons disease.Deutetrabenazine: Approved in April 2017It is a vesicular monoamine transporter 2 VMAT2 inhibitor.Specifically indicated for the treatment of chorea associated with Huntingtons disease.Supplied as a tablet for oral administration.Safinamide:MAO B inhibitor.Approved for treatment of on off phenomena seen with levodopa in parkinsons disease. 